NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
University of California, San Francisco
National Cancer Institute (NCI)
AstraZeneca
I-Mab Biopharma US Limited
Centre Leon Berard
Gustave Roussy, Cancer Campus, Grand Paris